Table: Taisho Pharmaceutical HD -Q1 group results
Aug 1 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2018 Jun 30, 2017 Mar 31, 2019
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 61.75 68.53 269.00
(-9.9 pct) (-1.3 pct) (-4.0 pct)
Operating 8.16 6.94 33.00
(+17.5 pct) (-23.8 pct) (-10.8 pct)
Recurring 12.21 8.80 39.50
(+38.8 pct) (-15.6 pct) (-6.3 pct)
Net 13.69 5.53 55.50
(+147.3 pct) (-20.3 pct) (+75.2 pct)
EPS 171.50 yen 69.27 yen 694.62 yen
EPS Diluted 171.35 yen 69.21 yen
Ann Div 110.00 yen 110.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 60.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10